Skip to main content

Table 6 Association between patient variables and the occurrence of adverse events with anakinra treatment

From: Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey

 

Any adverse event

Non cutaneous adverse event

Patient variables

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

 

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

Paediatric vs. adult

5.67 (2.37 to 13.60)

0.0001

3.27 (1.16 to 9.21)

0.03

1.83 (0.90 to 3.73)

0.10

-

n.s.

Treatment duration

2.12 (1.15 to 3.89)

0.02

-

n.s

2.61 (1.34 to 5.13)

0.005

3.37 (1.46 to 7.80)

0.01

Background treatment:

Methotrexate

0.44 (0.21 to 0.95)

0.03

-

n.s.

0.61 (0.26 to 1.41)

0.25

-

n.s.

All DMARDs

0.47 (0.23 to 0.98)

0.04

0.27 (0.11 to 0.64)

0.003

0.72 (0.33 to 1.59)

0.42

  

Corticosteroids

1.17 (0.57 to 2.38)

0.68

  

0.82 (0.38 to 1.75)

0.62

  

NSAIDs

1.38 (0.58 to 3.29)

0.47

  

0.67 (0.26 to 1.74)

0.41

  

Disease:

AOSD

1.36 (0.72 to 2.57)

0.35

-

n.s.

0.91 (0.46 to 1.79)

0.78

  

sJIA

6.53 (1.87 to 22.7)

0.004

-

n.s.

1.42 (0.58 to 3.48)

0.45

  

Gout

0.06 (0.02 to 0.21)

0.0001

0.05 (0.001 to 0.24)

0.0002

0.07 (0.01 to 0.51)

0.01

-

n.s.

CAPS

1.37 (0.52 to 3.61)

0.53

-

n.s.

1.97 (0.77 to 5.10)

0.16

-

n.s.

  1. OR: odds ratio. 95% CI: 95% confidence interval, DMARDs: disease-modifying anti-rheumatic drugs, NSAIDs : non-steroidal anti-inflammatory drugs, AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin associated periodic syndrome. n.s.: not significant.
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172